<DOC>
	<DOC>NCT01352338</DOC>
	<brief_summary>Study Phase: phase 1 and phase 2 Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide Study design: prospective, multicenter, non-randomized</brief_summary>
	<brief_title>Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)</brief_title>
	<detailed_description>The REPEAT-study is a prospective, multicenter, non-randomized phase 1 and phase 2 study in which we evaluate the effect of lenalidomide, cyclophosphamide and prednisone (REP-therapy) in patients with relapsed multiple myeloma, previously treated with lenalidomide and refractory to lenalidomide monotherapy.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>salmon &amp; Durie stage II/III A or B previous lenalidomide refractory disease patient commits to pregnancy prevention programme nonsecretory myeloma known hypersensitivity to lenalidomide inadequate marrow reserve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>REPEAT</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>revlimid</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>endoxan</keyword>
	<keyword>prednisone</keyword>
	<keyword>lenalidomide refractory</keyword>
</DOC>